National Research Corporation (NRC) stands at the nexus of healthcare and data analytics, providing crucial insights that empower healthcare organizations to enhance patient and employee experiences. Founded in 1981 and headquartered in Lincoln, Nebraska, NRC operates within the healthcare sector, specifically in health information services. With a market capitalization of $318.79 million, NRC is a notable player in this niche but vital segment of the industry.
Currently, NRC’s stock is trading at $14.07 with a modest price uptick of 0.29 (0.02%). Over the past year, the stock price has fluctuated within a range of $10.13 to $21.29, indicating potential volatility, yet also the possibility for significant upside for investors who time their entry strategically.
A standout metric for NRC is its impressive Return on Equity (ROE) of 66.87%, which suggests a highly efficient use of shareholders’ equity to generate profits. This is notably high compared to industry norms and could be a compelling factor for investors seeking robust returns on their investment. However, it’s important to note that NRC has been experiencing a revenue decline of 3.40%, which might raise concerns about its growth trajectory and market competitiveness.
Investors might find NRC’s dividend yield of 3.93% attractive, especially in an environment where consistent income streams are valued. The company’s payout ratio stands at 67.61%, indicating a balanced approach to rewarding shareholders while retaining capital for business operations and potential future growth.
Interestingly, no analysts have currently issued a buy, hold, or sell rating on NRC, which might suggest that the stock is flying under the radar. This absence of coverage could present an opportunity for individual investors to explore the stock’s intrinsic value without the influence of widespread analyst sentiment.
From a technical perspective, NRC’s stock is trading above its 50-day moving average of 13.60 but below its 200-day moving average of 14.36. The Relative Strength Index (RSI) of 43.71 suggests that NRC is neither overbought nor oversold, potentially signaling a stable entry point for investors. Meanwhile, the MACD indicator at 0.12, with a signal line of -0.21, indicates a bullish trend in the short term.
NRC’s offerings are extensive, ranging from patient experience and employee engagement solutions to advanced AI-driven platforms like Huey AI, underscoring its commitment to innovation in healthcare experience management. This diversified portfolio not only enhances its value proposition but also positions NRC as a key player in facilitating healthcare transformations through data-driven insights.
For investors, NRC represents a unique blend of high efficiency, steady dividends, and innovative service offerings in the healthcare information sector. While challenges in revenue growth warrant careful consideration, the company’s strong ROE and dividend yield present attractive features for those looking to invest in an underappreciated segment of the market. As healthcare continues to evolve, NRC’s role in providing actionable insights could prove increasingly invaluable, offering potential long-term rewards for patient investors.
